Services Design Development Scientific Advice Project Management QA – Quality Assurance Monitoring Clinical Performance Data Management/eTrials Biostatistics Medical Writing Expert Statement Expertise Pharmacokinetics BA/BE Interactions Oncological trials Ophthalmological trials Inhalatives Transdermal Therapeutic Systems Children Sexual Hormones Therapeutic Expertise Clinical Development Phase I Phase II / Proof of Concept Phase III in OTC Phase III Non-Interventional Magnetic Marker Monitoring Medical Devices Nutrition Studies Clinical Pharmacology Unit Location Plan Capacity Technical Monitoring Ophthalmology Gynaecology Intensive Assessment Unit Clean Room Area Archive About Us Goals and Visions Our Experts Science Quality Library Presentations Library Publications Locations Career News 3rd GBHI conference – program is online Who is a healthy subject? German Pharm-Tox Summit 2017 in Heidelberg 2nd part of Introductory Course in Exploratory Medicines Development scheduled for February 2017 Introductory Course in Exploratory Medicines Development – taking place in our offices in Oberursel! 2nd Global Bioequivalence Harmonisation Initiative – a great success Probanden The SocraTec Family SocraTec C&S SocraMetrics Cooperations
Anaesthesiologist NIS AGAH Pituitary Healthy subjects DPI Sample size estimation MDI Dry powder inhaler Lung Statistical Analysis Plan Children Efficacy Legal representative OTC Phase I Unit Pharmacokintetics Sequential designs Glaucoma Patch adhesion SDV Protocol Adrenocortical Source Data Verification Oncologic network CRF Pharmacology Data management Phase I Inhalatives Hormone replacement therapy Informed Consent Procedure Dose linearity WinNonlin Recruitment rates HRT Safety GCP training Charcoal Pharmacokinetics Experience Local tolerability Drug Food Interaction Phase II DFI Consultancy IVIVC Oncological patients Pilot study Design development Eye disease Clinical trials ADAM US CFR 21 Part 11 IEC Data Management Plan Quality Assurance Patients Product development Database MCID Xerostomia COPD Pharmacodynamic studies Clinical development program CRA Thuringia Life cycle management Rhine Main area Inspection ANVISA Allergy First in human Monitoring Clinical pharmacology unit Phase IIa trials Authorities EMA Protocol development Good Clinical Practice Macular HTA GCP Cardiovascular surveillance Sensitisation trials Gynaecological trials Standard operating procedure CRO Copyright Project Management Pulse oximetry plethysmography Asthma Paediatricians PASS Postmenopausal women FDA CDSIC Training Post authorisation Clinical Monitoring Competence DDI Statistical programming Dermal irritation Phase III Edema Non interventional Biosimilars Standardisation Phase IV Audit Ophthalmology Highly variable drugs Transdermal therapeutic system Oncology IB Dry eye Absorption Contraception Creativity Intensive assessment station Central surveillance system Sore throat Centralised procedure In vitro in vivo correlation Steady state Bioavailability Ovulation inhibition FIM Biopharmaceutics HPA axis Scientific advice Absorption windows Auditing Quality Cough SAS Data Validation Plan Axis Ophthalmologist Legal Information Biometrics Patch Phase IIb trials Quality Management System Female adolescents Endpoint Scientific expertise Clinical study Biopharmaceutical Investigators brochure Statistical services Feasibility Spacious archive Bioequivalence Uveitis Pragmatism Referral system Subcontractor qualification Ocular tolerability CDASH IMPD CDISC Slit lamp microscopy TTS Elpro Common cold Hypothalamic Metered dose inhaler SOP based SocraTec C&S Patient recruitment MMM Expert US FDA Early phase Degeneration DUS ICF Network Ophthalmological trials GLP Immunogenicity PAES Drug Drug Interaction CDM  
 
Menu

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All fine on front page